Materials and
Methods
Between 1 June- 31 December 2019, 224 patients with moderate-severe acne
vulgaris who administered oral ISO (0.5-1 mg/kg/day) at the Department
of Dermatology and Venereology of the Regional Training and Research
Hospital were included in this study. Written consent forms were
obtained from 203 adult patients and parents of 21 adolescent patients.
Patients who used any medication (iron, vitamin supplements, statins,
etc.) that could affect hematological parameters and lipid profile in
the last 3 months were excluded. All patients were selected from the
group of 15-35 years of age to be able to minimize the possibility of
atherosclerosis comorbidity as it may affect the inflammatory
parameters. Patients with cancer, severe infection, hematological
diseases (including iron-deficiency anemia), heart failure, and lung
diseases were excluded. Data such as gender, age, CBC, lipid profile,
and the serum alanine aminotransferase (ALT), aspartate aminotransferase
(AST), blood urea nitrogen (BUN), creatinine, and uric acid levels were
obtained from the electronic registration database. In the pre-treatment
phase and 3 months after treatment, white blood cell (WBC), neutrophil,
lymphocyte, monocyte and platelet counts, MPV, PTC, NLR, PLR,
monocyte/lymphocyte ratio (MLR), MHR, serum triglyceride (TG), total
cholesterol, high-density lipoprotein (HDL), and low-density lipoprotein
(LDL) levels were analyzed.
This single-center cross-sectional retrospective-study was approved by
the Ethics Committee of the Regional Training and Research Hospital,
Erzurum, Turkey (Decision No: 2020/12-134). This study was conducted per
the latest version of the ”Helsinki Declaration” and ”Guidelines for
Good Clinical Practice”.